Cereno Scientific

"Participating at a key pulmonary vascular congress such as PVRI is an important aspect of our strategy to continue to raise awareness about our exciting portfolio in the field. This year's theme focused on the global future of pulmonary hypertension, aligns greatly with our mission to transform the treatment of the rare disease pulmonary arterial hypertension (PAH). We are looking forward to making valuable connections and interact with others in the field," said Sten R. Sörensen, CEO, Cereno Scientific.

The delegation from Cereno comprises Raymond L. Benza, Chief of Pulmonary Hypertension for the Mount Sinai Health System, New York City, Principal Investigator of the Phase II study of CS1 in PAH, and member of Cereno's Scientific Advisory Board; Sten R. Sörensen, Chief Executive Officer, Cereno; and Björn Dahlöf, Chief Medical Officer, Cereno.

The Pulmonary Vascular Research Institute (PVRI) is a charity that brings together the best medical professionals in the world who have an interest in pulmonary hypertension or pulmonary vascular disease. PVRI facilitates global research and development of medicines for the treatment of pulmonary hypertension and other pulmonary vascular diseases. Attendees at the PVRI World Congress include medical professionals, drug regulatory bodies and professionals from the pharmaceutical industry.

For further information, please contact:

Tove Bergenholt, Director IR & Communications

Email: tove.bergenholt@cerenoscientific.com

Phone: +46 732-366 246

Sten R. Sörensen, CEO

Email: sten.sorensen@cerenoscientific.com

Phone: +46 73-374 03 74

About Cereno Scientific AB

Cereno Scientific develops innovative treatments for common and rare cardiovascular disease. The lead drug candidate, CS1, is a HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties. A Phase II study is ongoing to evaluate CS1's safety, tolerability, and efficacy in patients with the rare disease pulmonary arterial hypertension (PAH). A collaboration agreement with global healthcare company Abbott allows Cereno to use their cutting-edge technology CardioMEMS HF System in the study. Two initiatives performed during the ongoing Phase II study have shown positive findings suggesting the potential clinical benefit of CS1 in PAH patients. These initial findings are, however, not a guarantee of the final study results that are expected in Q2 2024. After requests by investigators in the Phase II study, a "compassionate use" application for CS1 is currently being pursued. Cereno also has two promising preclinical drug candidates in development through research collaborations with the University of Michigan. Investigational drug CS014 is a HDAC inhibitor in development as a treatment for arterial and venous thrombosis prevention. The innovative drug candidate represents a groundbreaking approach to antithrombotic treatment potentially without the associated increased risk of bleeding in humans. CS014 is a new chemical entity with a multi-fold mechanism of action as an epigenetic modulator - regulating platelet activity, fibrinolysis, and clot stability for the prevention of thrombosis without increased risk of bleeding as documented in preclinical studies. Drug candidate CS585 is a prostacyclin receptor agonist that has been documented in several preclinical studies to target the IP receptor for prevention of thrombosis without increased risk of bleeding, which also has been recognized in the medical community. CS585 was in-licensed from the University of Michigan in 2023. The company is headquartered in Gothenburg, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Nasdaq First North (CRNO B). More information on www.cerenoscientific.com.